Description
|
Catalog #
|
CAS#
|
Target
|
Size
|
Price ( $)
|
JAK3 INHIBITOR NEGATIVE CONTROL
4-Phenylamino-6,7-dimethoxyquinazoline, HCl, WHI-P258, HCl
|
SMBC1032
|
|
A useful negative control for JAK3
inhibitors ( Catalog# SMBC1033,
SMBC1034)
|
1 mg
|
135
|
JAK3 INHIBITOR I,
4-(4′-Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, WHI-P131
|
SMBC1033
|
202475-60-3
|
A cell-permeable, reversible,
potent, ATP-competitive, and
specific inhibitor of JAK3 (Janus
family kinase 3; IC50 = 78 µM).
Has no effect on JAK1, JAK2, or
Zap/Syk or Src tyrosine kinases.
|
5 mg
|
120
|
JAK3 INHIBITOR II
4-[(3′-Bromo-4′-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, WHI-P154
|
SMBC1034
|
211555-04-3
|
A potent, cell-permeable,
reversible, ATP-competitive, and
specific inhibitor of JAK3 (IC50 =
5.6 µM). Has no effect on either
JAK1 or JAK2. Has also been
shown to prevent the ionizing
radiation-induced activation of
c-Jun in DT-40 cells.
|
5 mg
|
150
|
SU 5416 VEGFR2 KINASE INHIBITOR III
3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one, SU5416, Vascular
Endothelial Growth Factor Receptor 2 Kinase Inhibitor III
|
SMBC1035
|
204005-46-9
|
A cell-permeable indolinone
compound that acts as a
selective, reversible, and
ATP-competitive inhibitor of
VEGF-R (KDR/Flk-1) and
PDGF-R tyrosine kinases (IC50 =
1.04 µM and 20 µM in NIH 3T3
cells overexpressing Flk-1; Km =
530 nM for ATP). Also potently
inhibits the proliferation of
HUVECs induced by VEGF,
bFGF, or ECGS (IC50 = 50 nM,
5.3 µM and 30.5 µM, respectively).
Blocks the autophosphorylation
of internal tandem duplication
(ITD) and wild type Fms-like
tyrosine kinase 3 (FLT3) with an
IC50 of 0.1 µM.
|
1 mg
|
120
|
COMPOUND 52,
2-(2-Hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine
|
SMBC1036
|
212779-48-1
|
A potent, cell-permeable,
reversible, selective, and
ATP-compatible inhibitor of the
cell cycle-regulating kinase,
Cdc28p (IC50 = 7 µM), and the
related Pho85p kinase (IC50 = 2
µM).
|
1 mg
|
80
|
Bohemine,
[6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine
|
SMBC1037
|
189232-42-6
|
A synthetic, cell-permeable,
cyclin-dependent kinase (CDK)
inhibitor (IC50 = 1 µM)
|
1 mg
|
45
|
Bohemine,
[6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine
|
SMBC1037
|
189232-42-6
|
A synthetic, cell-permeable,
cyclin-dependent kinase (CDK)
inhibitor (IC50 = 1 µM)
|
5 mg
|
135
|
AG 1296
6,7-Dimethoxy-3-phenylquinoxaline
|
SMBC1038
|
146535-11-7
|
A cell-permeable, reversible, and
ATP-competitive, inhibitor of
PDGF receptor kinase and
blocks signaling of human PDGF
α-receptors (IC50 = 1.0 µM) and
β-receptors (IC50 = 800 nM) as
well as of the related stem cell
factor receptor c-kit (80%
inhibition at 5 µM).
|
5 mg
|
95
|
AG 1295
6,7-Dimethyl-2-phenylquinoxaline
|
SMBC1039
|
71897-07-9
|
A cell-permeable, reversible,
ATP-competitive, and selective
inhibitor of platelet-derived
growth factor (PDGF) receptor
kinase (IC50 = 500 nM) and
PDGF-dependent DNA synthesis
(IC50 = 2.5 µM) in Swiss/3T3
cells.
|
5 mg
|
95
|
AG 490
α-Cyano-(3,4-dihydroxy)-N-benzylcinnamide, Tyrphostin B42, (E)-N-benzyl-2-
cyano-3-(3,4-dihydroxyphenyl)acrylamide
|
SMBC1040
|
133550-30-8
|
A cell-permeable, reversible,
substrate competitive, and potent
inhibitor of epidermal growth
factor receptor kinase
autophosphorylation (IC50 = 100
nM). Inhibition of JAK2 by AG 490
selectively blocks leukemic cell
growth in vitro and in vivo by
inducing programmed cell death,
with no harmful effect on normal
hematopoiesis. Inhibits the
constitutive activation of STAT-3
DNA binding and IL-2-induced
growth of MF tumor cells.
|
5 mg
|
45
|
AG 538
α-Cyano-(3,4-dihydroxy)cinnamoyl-(3′,4′-dihydroxyphenyl)ketone, Tyrphostin
AG 538
|
SMBC1041
|
133550-18-2
|
A potent, cell-premeable,
reversible, and competitive
inhibitor of IGF-1 receptor kinase
(IC50 = 400 nM). Reaction is
competitive with respect to
IGF-1R substrate. Also inhibits
the phosphorylation of PTK
substrate poly(Glu,Tyr) by IGF-1R,
IR, EGF-R, and Src (IC50 = 60
nM, 113 nM, 370 nM, and 2.4 µM,
respectively). Inhibits the
phosphorylation of PKB at a
much higher concentration (IC50
= 76 µM).
|
5 mg
|
72
|
AG 82
α-Cyano-(3,4,5-trihydroxy)cinnamonitrile, Tyrphostin A25
|
SMBC1042
|
118409-58-8
|
A cell-permeable, reversible, and
competitive inhibitor of substrate
binding on protein tyrosine
kinases. Inhibits epidermal
growth factor receptor tyrosine
kinase (IC50 = 3 µM) and the
GTPase activity of transducin
(IC50 = 7 µM). Inhibits
neuromedin B-induced
phosphorylation of p125FAK
(focal adhesion kinase). Blocks
the induction of inducible nitric
oxide synthase in glial cells.
Induces apoptosis in human
leukemic cell lines.
|
5 mg
|
55
|
AG 825
4-Hydroxy-3-methoxy-5-(benzothiazolylthiomethyl)benzylidenecyanoacetamide
|
SMBC1043
|
|
A potent, cell-premeable,
reversible, substrate competitive,
and selective inhibitor of HER2
(neu/ErbB2; IC50 = 0.35 µM)
relative to HER1 (IC50 = 19 µM)
autophosphorylation. The
inhibition is competitive with
respect to ATP binding.
|
5 mg
|
95
|
AG 1024
3-Bromo-5-t-butyl-4-hydroxy-benzylidenemalonitrile
|
SMBC1044
|
|
A cell-permeable, reversible,
substrate competitive, and
specific inhibitor of insulin-like
growth factor-1 (IGF-1) and
insulin receptor tyrosine kinase
activity. Exhibits lower IC50
values for IGF-1 than for the
insulin receptor. Also inhibits
insulin-stimulated cellular
proliferation.
|
1 mg
|
78
|
AG 879
α-Cyano-(3,5-di-t-butyl-4-hydroxy)thiocinnamide
|
SMBC1045
|
148741-30-4
|
A cell-permeable, reversible, and
substrate competitive inhibitor of
nerve growth factor (NGF)-
dependent p140c-trk tyrosine
phosphorylation (EC50 = 10 µM)
as well as NGF-induced
phospholipase C-γ1
phosphorylation. Also blocks
NGF-induced neurite outgrowth
in PC12 cells.
|
5 mg
|
100
|
NIR 5e
|
CUS313
|
162411-31-6
|
BioReagent suitable for
Fluorescence
|
1 mg
|
100
|
NIR 5e
|
CUS313
|
162411-31-6
|
BioReagent suitable for
Fluorescence
|
5 mg
|
400
|
NIR 4f
|
CUS314
|
162411-24-7
|
BioReagent suitable for
Fluorescence
|
1 mg
|
100
|
NIR 4f
|
CUS314
|
162411-24-7
|
BioReagent suitable for
Fluorescence
|
5 mg
|
400
|
9-Hyrdoxyellipticine, Hydroch
loride
|
CUS333
|
52238-35-4
|
A cell-permeable antitumor
alkaloid that acts as a potent
inhibitor of topoisomerase II
|
10 mg
|
70
|
9-Hyrdoxyellipticine, Hydroch
loride
|
CUS333
|
52238-35-4
|
A cell-permeable antitumor
alkaloid that acts as a potent
inhibitor of topoisomerase II
|
50 mg
|
350
|
L-Alanyl-L-1-aminoethylphosphonic acid, Alafosfalin
|
CUS369
|
60668-24-8
|
Antibacterial-Cell wall Synthesis
|
250mg
|
160
|
Bestatin hydrochloride
|
CUS375
|
65391-42-6
|
reversible inhibitor of
aminopeptidase enzymes,
namely Aminopeptidase B,
Aminopeptidase M, and leucine
aminopeptidase. Inhibition of
these proteins by Bestatin
correlates to apoptosis induction
in oncogenic cells. Bestatin is
also a potent inhibitor of
leukotriene A4 hydrolase (LTA4),
potentially allowing investigation
of the role of LTA4 in
inflammation.
|
25 mg
|
250
|
